Like its effects on BRCA cells, ERCC6L potentiates the growth of HCC cells, and as downstream effectors of ERCC6L, the pro-cancerous pathways; PI3K/AKT and NF-κB, are activated [18, 19]. Here, AKT1 is linked to hepatocellular carcinoma.